Organogenesis (ORGO) Expected to Release Quarterly Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.1750) per share and revenue of $52.10 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.36). Organogenesis had a negative net margin of 19.94% and a negative return on equity of 23.89%. The business had revenue of $43.76 million for the quarter, compared to the consensus estimate of $54.27 million.

Organogenesis Trading Up 3.5%

Shares of ORGO stock traded up $0.03 on Tuesday, hitting $0.78. 20,065 shares of the company’s stock traded hands, compared to its average volume of 999,816. The stock has a market capitalization of $100.63 million, a price-to-earnings ratio of -0.91 and a beta of 1.27. The company’s fifty day simple moving average is $1.33 and its 200 day simple moving average is $2.37. Organogenesis has a one year low of $0.73 and a one year high of $7.08. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.00 and a current ratio of 3.52.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ORGO. Wall Street Zen raised Organogenesis from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 19th. Weiss Ratings lowered Organogenesis from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, October 19th. Finally, Truist Financial lowered their target price on Organogenesis from $3.00 to $2.00 and set a “hold” rating for the company in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Organogenesis has an average rating of “Reduce” and a consensus target price of $4.33.

Organogenesis Company Profile

Organogenesis Holdings Inc is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue.

Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.